SLP News and Press, Simulations Plus Inc. From 01/03/24

2024-01-03 19:54:09 ET Simulations Plus, Inc. (SLP) Q1 2024 Earnings Conference Call January 03, 2024, 05:00 PM ET Company Participants Tamara Gonzalez - Investor Relations, Financial Profiles Shawn O'Connor - Chief Executive Officer Will Frederick - Chief Financ...

2024-01-03 16:10:49 ET More on Simulations Plus Big Pharma's AI Ambitions: The Countdown For Simulations Plus Begins Simulations Plus, Inc. (SLP) Q4 2023 Earnings Call Transcript Simulations Plus director sells stock worth $2.3M - filing Seeking Alpha’...

Total revenue of $14.5 million and diluted earnings per share (EPS) of $0.10 Maintains full-year revenue guidance of $66 to $69 million (+10-15%) and EPS guidance of $0.66 to $0.68 Simulations Plus, Inc. (NASDAQ: SLP) (“Simulations Plus”), a leading provider of mod...

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the following leadership changes effective January 3, 2024. “We are excited to announce...

2023-12-29 15:00:18 ET More on the markets Sentiment Speaks: The Fed Is Going To Put A Big Hurt On Everyone In 2024 5 Big Market Predictions For 2024 2024 Analyst Outlook: Lawrence Fuller On An Economic Soft Landing Scenario A Peak In Excess Liquidity May Mea...

2023-12-26 15:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Conference call to be on Wednesday, January 3, 2024, at 5 p.m. EST Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report first quarter fiscal 2024 financial results after the market close on Wednesday, January 3, 2024. Managem...

2023-12-10 13:04:00 ET More on AbCellera Biologics, Absci, etc. AbCellera: Difficult 2023 Suggests Business Model Should Pivot In 2024 Buy AbCellera Biologics's Revolutionizing AI-Powered Drug Development Platform Certara, Inc. 2023 Q3 - Results - Earnings Call Prese...

2023-12-10 08:00:00 ET More on AI's impact Nvidia Shares Now Look Cheap (Rating Upgrade) Snowflake's Data Marketplace: The Key To Unlocking The Potential Of Generative AI Microsoft Corporation (MSFT) Presents at Barclays Global Technology Conference (Transcript) ...

2023-12-06 14:31:18 ET More on Simulations Plus Big Pharma's AI Ambitions: The Countdown For Simulations Plus Begins Simulations Plus Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Simulations Plus Historical earnings data for Simulat...